Pasar al contenido principal

IDENTIFICACION EN SANGRE DE RESISTENCIAS A TRATAMIENTOS SISTEMICOS EN CANCER DE MAMA METASTASICO SUBTIPOS LUMINAL

PI18/00183

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiplex real-time PCR in non-invasive respiratory samples to reduce antibiotic use in community-acquired pneumonia, a randomised trial

  • Abelenda-Alonso, Gabriela|||0000-0001-8158-9934
  • Calatayud, Laura|||0000-0001-6182-4538
  • Rombauts, Alexander|||0000-0003-0227-5916
  • Meije, Yolanda
  • Oriol, Isabel|||0000-0001-5542-7878
  • Sopena, Nieves|||0000-0001-6382-9500
  • Padullés, Ariadna|||0000-0003-1541-6001
  • Niubó, Jordi|||0000-0001-9511-0138
  • Duarte, Alejandra
  • Llaberia-Marcual, Jaume|||0000-0002-8675-2777
  • Aranda, Judit
  • Gudiol, Carlota|||0000-0003-3095-4422
  • Satorra, Pau|||0000-0002-8144-4089
  • Tebé, Cristian|||0000-0003-2320-1385
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Carratalà, Jordi|||0000-0003-3209-2563
We assessed whether multiplex real-time PCR plus conventional microbiological testing is safe and more effective than conventional microbiological testing alone for reducing antibiotic use in community-acquired pneumonia (CAP). In this randomised trial, we recruited adults hospitalised with CAP at four Spanish hospitals. Patients were randomly assigned (1:1) to undergo either multiplex real-time PCR in non-invasive respiratory samples plus conventional microbiological testing or conventional microbiological testing alone. The primary endpoint was antibiotic use measured by days of antibiotic therapy (DOT). Between February 20, 2020, and April 24, 2023, 242 patients were enrolled; 119 were randomly assigned to multiplex real-time PCR plus conventional microbiological testing and 123 to conventional microbiological testing alone. All but one of the patients allocated to multiplex real-time PCR plus conventional microbiological testing underwent PCR, which was performed in sputum samples in 77 patients (65.2%) and in nasopharyngeal swabs in 41 (34.7%). The median DOT was 10.04 (IQR 7.98, 12.94) in the multiplex PCR plus conventional microbiological testing group and 11.33 (IQR 8.15, 16.16) in the conventional microbiological testing alone group (difference -1.04; 95% CI, -2.42 to 0.17; p = 0.093). No differences were observed in adverse events and 30-day mortality. Our findings do not support the routine implementation of multiplex real-time PCR in the initial microbiological testing in hospitalised patients with CAP. Clinicaltrials.gov registration: NCT04158492.